Crossmark

Caplacizumab: First Global Approval

Crossref DOI link: https://doi.org/10.1007/s40265-018-0989-0

Published Online: 2018-10-08

Published Print: 2018-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Duggan, Sean
License Information

Text and Data Mining valid from 2018-10-01
More Information

Article History

First Online: 8 October 2018

Change Date: 3 December 2018

Change Type: Correction

Change Details: The article Caplacizumab: First Global Approval, written by Sean Duggan, was originally published Online First without open access.

Compliance with Ethical Standards

:

: The preparation of this review was not supported by any external funding.

: During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Sean Duggan is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.